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Abstract
Thirty two patients with active Crohn's disease
were included in a controlled randomised
trial to determine the efficacy and safety of
polymeric enteral nutrition compared with
steroids, to achieve and maintain clinical
remission. The polymeric diet was admin-
istered through a fine bore nasogastric tube by
continuous, pump assisted infusion (2800
(SEM 120) kcal/day). The steroid group
received 1 mg/kg/day ofprednisone. Both treat-
ments were effective in inducing clinical remis-
sion: 15 of the 17 patients given steroids and 12
ofthe 15 patients assigned to the polymeric diet
went into clinical remission (defined by a Van
Hees index <120) within four weeks of treat-
ment. The percentage reduction of the Van
Hees index was 34*8 (4.9)% for steroids and
32 3 (5)% for enteral nutrition (mean difference
2-5%; 95% CI -11-8% to +16-8%). Mean time
elapsed to achieve remission was similar in
both groups (2.0 (1) v 2-4 (1.2) weeks). Toler-
ance of the enteral diet was excellent. Four
patients in the steroid group had mild com-
plications attributable to this treatment. Ten
patients (66.6%) in the steroid group and five
(41.6%) in the enteral nutrition group relapsed
within a year of discharge, but no differences
were found in the cumulative probability of
relapse during the follow up period. These
results suggest that polymeric enteral nutrition
is as safe and effective as steroids in inducing
short term remission in active Crohn's disease.
(Gut 1993; 34: 778-782)
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Elemental (aminoacid based) diets were initially
introduced as primary treatment of active
Crohn's disease because of their hypoaller-
genicity, because it was considered that whole
protein may act as a dietary antigen and increase
the immune stimuli to the gut.' Another argu-
ment for these diets was their possible role in
favouring bowel rest. Six prospective random-
ised trials have evaluated the efficacy of
elemental diets in Crohn's disease. In four of
them, the elemental diet was as effective as
steroid treatment in achieving short term remis-
sion. '-4 In one trial, elemental feeding was as
effective as bowel rest plus total parenteral
nutrition,5 but these results could not be repro-
duced in patients with colonic Crohn's disease.8
Recent studies suggest that the effectiveness of
elemental formulas is sustained by factors other
than the so called bowel rest.78 Also, polymeric
(whole protein based) diets, when used as
adjuncts to steroids, are well tolerated in active
Crohn's disease.9 Elemental diets have the incon-
venience, however, of being unpalatable, hyper-
osmolar, and expensive. Therefore, other types
of formula diets without such drawbacks have
been assessed. In one study, hydrolysed (peptide
based) diets were no better than steroid plus
sulfasalazine treatment.'0 In another trial this
type of diet was as effective as an elemental diet
in inducing remission in active Crohn's disease."
Four prospective randomised trials have investi-
gated the role of polymeric formulas in Crohn's
disease. In three of them, this diet was as
effective as an elemental diet in achieving remis-
sion.'2 14 By contrast, opposite results were
obtained in a recent study, with a very poor
response to the polymeric diet.'5 Thus the
question of which type of enteral formula diet is
better in the treatment of Crohn's disease
remains open, and a study comparing polymeric
diets with steroid treatment has, to our know-
ledge, never been performed.
The aim of the present study was to evaluate
the efficacy and safety of polymeric enteral
nutrition, as compared with steroid treatment, in
achieving and maintainimg clinical remission in
patients with active Crohn's disease.
Patients and methods
From November 1988 until November 1991, all
adult patients admitted because of clinically
symptomatic Crohn's disease were prospectively
evaluated. The diagnosis ofthe disease was based
on previously reported clinical, morphological,
and histopathological data.'6 Patients were con-
sidered for the trial on the basis of: (1) symptoms
consistent with activity of the disease (abdominal
pain, diarrhoea, weight loss, anorexia, fever);
(2) two or more abnormal laboratory indices
indicative of active disease (erythrocyte sedi-
mentation rate (ESR). >30 mm/h, haemoglobin
concentration (Hb) <12 g/dl for men and
< 11 5 g/dl for women, C-reactive protein (CRP)
>3 mg/l, platelet count >350000 cells/mm3);
and (3) Van Hees activity index (VHAI)'7 greater
than 120.
Patients were excluded from the study if they
were already taking steroids, had evidence of
intestinal perforation, significant intestinal
obstruction, toxic megacolon, massive gastro-
intestinal haemorrhage, or mid-jejunal fistulas
that precluded the use of enteral nutrition.
Forty four patients with Crohn's disease were
examined for eligibility during the trial period.
Twelve were excluded because of VHAI <120
(five patients), steroid treatment (four patients),
refusal to participate in the study (two patients),
and mental retardation (one patient). Thus 32
patients (17 men, 15 women) were assigned by
means of a random number table to one of two
treatment groups: 17 patients were treated with
778
 group.bmj.com on April 5, 2011 - Published by gut.bmj.comDownloaded from 
Polymeric enteral diets asprimary treatment ofactive Crohn's disease: a prospective steroid controlled trial
TABLE I Composition ofthe polymericformula diet*
Proteins (g/l) 54 60 (22%)
Lipids (g/l) 36-20 (32%)
Carbohydrates (g/l) 114-20 (46%)
Energy content 1 kcal/ml
Energy-nitrogen ratio (non-protein kcal/g N) 91-5
Nitrogen (g/l) 8-73
Osmolality (mOsm/kg) 278
Energy source
Nitrogen Intact milk protein
Fat 13% MCT, 28% saturates, 41% monounsaturates,
18% polyunsaturates
Carbohydrate Maltodextrins
Daily energy supply (kcal/day) 2800 (120)
Daily N supply (g N/day) 24-3 (1-5)
*Edanec HN (UNIASA, Granada, Spain). Vitamin and trace element content in the upper limit of the
recommended daily allowance for 2000 kcal.
MCT=Medium chain triglycerides.
steroids and 15 patients received a polymeric
diet. To obtain comparable groups a stratified
randomisation was performed according to two
variables: the VHAI (<170 v >170), and the
location of the disease (small bowel (with or
without colon involvement) v exclusive colonic
disease). The study was performed in accordance
with the guidelines of the Declaration of
Helsinki. Informed consent was obtained from
all the patients and the study was approved by
the research and ethics committees of both
participating hospitals.
Table I gives the composition of the polymeric
formula diet. Polymeric enteral nutrition (PEN)
was administered through a fine bore Silk type
nasogastric tube (Corpak, Chicago, IL) by con-
tinuous, pump assisted infusion over 20-22
hours/day. No oral food or fluids were allowed
during the trial. Daily total caloric requirements
were calculated from Long's equation modified
for ideal body weight.'8 A starter regimen was
used, with infusion of60% of the calculated total
caloric requirements on the first day; this was
progressively increased to 100% by the third day.
Patients randomised for steroid treatment
received oral prednisone (1 mg/kg/day). If
improvement was achieved, prednisone was
gradually reduced by 10 mg weekly decrements
down to 30 mg. Afterwards, prednisone was
reduced in steps of 5 mg/week until completely
withdrawn. While in hospital, patients taking
steroids were encouraged to eat the whole
hospital lactose free diet (mean daily caloric
intake 2200 (230) kcal/day).
In both groups, treatment with sulfasalazine,
azathioprine, cyclosporine A, or parenteral
nutrition was not allowed. Two patients, one in
each group, received oral metronidazole (20
mg/kg/day) for severe perianal disease.
EVALUATION OF RESPONSE
Improvement was defined as showing three or
less stools a day, absence or mild abdominal
pain, no fever, pulse rate 690 beats/min, and a
10% reduction in the VHAI in each weekly
evaluation of the patient. Clinical remission was
considered when a patient fulfilled the criteria of
improvement and had a VHAI < 120.
Patients not fulfilling the criteria of improve-
ment, and those in whom the VHAI increased
compared with that of the previous weekly
evaluation, were considered as treatment failure
and treatment was stopped. Also, treatment was
considered unsuccessful when clinical remission
was not achieved after four weeks.
Laboratory evaluation, including complete
haematological and biochemical analysis (SMA-
21 plus autoanalyser), was obtained weekly.
Nutritional assessment was performed weekly
by recording body weight, percentage of ideal
body weight (% IBW), mid-arm muscle circum-
ference (MAMC, % standard), triceps skinfold
thickness (TSF, % standard), and serum
albumin concentration. 19
FOLLOW UP
After remission was achieved, a western type
lactose free oral diet was reintroduced in the
PEN group within a period no longer than two
days. In both groups, treatment with oral 5-ASA
(500 mg mesalazine thrice daily) was started
before discharge and maintained during follow
up. Patients treated with steroids continued the
decreasing steroid regime on an ambulatory basis
and also had a western type lactose free oral diet.
Milk derivatives were slowly reintroduced after
one month of follow up in both groups.
Follow up included monthly visits during the
first three months, and every three months
afterwards. Relapse was defined as: (1) appear-
ance of symptoms of flare up (abdominal pain or
diarrhoea) or development of complications of
the disease (intestinal occlusion, abdominal
mass, fistulas etc); (2) two or more of body
temperature >37 50C, ESR >30 mm/h, CRP >3
mg/l, platelet count >350 000 cells/mm'.
STATISTICAL CALCULATIONS
A sample size of 15 patients for each group was
calculated based on an a error of 0 05 and a i
error of 0-10 (two tailed).20 This number of
patients should allow us to detect a minimal
relevant difference in the mean percentage
reduction of the VHAI between both treatments
of 20% (35 points); the estimated standard
deviation of the VHAI is 30 points, a value
obtained from a previous study on patients with
similar clinical characteristics.2'
The results are expressed as mean (SEM). The
95% confidence intervals (95% CIs) for percent-
ages and for the difference between means were
computed when appropriate. Significant differ-
ences between both groups were determined by
the X2 test of independence or Fisher's exact test
and by the unpaired Student t test for qualitative
and quantitative data respectively. The effect of
treatment on laboratory and anthropometric
measurements was assessed by the paired
Student t test. Evolution of ordered categorical
data in each group was assessed by the Wilcoxon
rank sum test. Probability of relapse curves were
computed by the Kaplan-Meier method, and
were compared between groups by the long rank
test. All the statistical analyses were performed
with the statistical package BMDP (Statistical
Software Inc, Los Angeles, CA, 1989).
Results
Table II shows the main features in both treat-
ment groups. At entry, both groups were clinic-
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TABLE II Clinical and nutritional features ofthe patients at the beginning ofthe study
PEN
(n=15)
Age (y)
Sex (man/woman)
No of patients:
First attack
Location (colon/small bowel/mixed)
Extraintestinal complications
Perianal disease
Abdominal mass
No of bowel actions
Abdominal pain
Van Hees activity index
Temperature (°C)
Pulse rate (beats/min)
ESR (mm/h)
CRP (mg/l)
Body wt (kg)
Body wt loss (%)
% IBW
TSF (%)
MAMC (%)
Serum albumin (g/l)
Lymphocytes (cells/mm3)
31-1(4 1)
7/8
7
3/3/9
3
4
5
2-6 (0-4)
6
172 5 (7 7)
36 9 (0 1)
85-1 (2-5)
38-3 (5 8)
37-1 (6-1)
57 1 (3 4)
11-7 (2 9)
89-1 (3-6)
67 5 (7 8)
108-1 (2 9)
34-2 (1-2)
2099(220)
Steroids
(n= 17)
32-4 (3-7)
10/7
11
5/3/9
5
4
6
2-8 (0 6)
10
184-3 (9 5)
36-9(0-1)
83-8 (2 4)
47-7 (5*4)
44-1 (7 8)
57-8 (3-3)
11-7 (1-7)
86-9 (31)
72-9 (7 9)
96-5 (5-2)
33-6 (1-4)
1674 (150)
Values followed by parentheses are means (SEM).
PEN= Polymeric enteral nutrition; IBW=ideal body weight; TSF= triceps skinfold; MAMC=mid-
arm muscle circumference; there were no significant differences between groups.
ally and nutritionally comparable. The number
of patients with abnormal biological and nutri-
tional indices before and after the trial were
similar in both treatment groups (Table III).
Twenty seven patients achieved clinical remis-
sion: 15 out of 17 (88-2%; 95% CI 63-5-98-5) in
the steroid group, and 12 out of 15 (80%; 95% CI
51-9-95-7) in the PEN group (p=043). Mean
time to achieve remission was similar in both
groups (steroids: 2-0 (1-0) weeks v PEN: 2-4
(1-2) weeks; p=0 47). Nine cases achieved a
response within the first week (five prednisone,
four PEN), eight cases by the second week (six
prednisone, two PEN), five by the third week
(two prednisone, three PEN), and five by the
fourth week (two prednisone, three PEN). A
decrease in activity of disease was shown in both
groups by reduction in the VHAI (PEN: 172-5
(7-7) to 113-8 (6-9), p=0-0001; steroids: 184-3
(9 5) to 118-1 (10-6), p=0 0003). The percent
reduction of the VHAI was 34-8 (4 9)% for the
steroid group and 32-28 (5 0)% for the PEN
group. The 95% CI for the difference of 2-5%
ranged from -11-8% to 16-8% and included
zero. Tables IV and V show that the changes in
the VHAI in both groups were due to the
improvement in most items included in the
index. Also, CRP concentration significantly
decreased in both treatment groups.
Treatment failure occurred in two patients of
the steroid group, both within the first week.
One of them had an intestinal perforation and
required surgery. The second patient was treated
with enteral diet and achieved remission. In the
TABLE III Number ofpatients with abnormal biological and
nutritional indices before and after the trial
Pen (n=15) Steroids (n= 17)
Initial Final Initial Final
CRP>3mg/l 14 11 15 11
ESR >30 mm/h 11 4 12 5
Serum albumin <33 g/l 6 1 7 2
Platelets >350x 109/l 9 6 13 12
Hb<12g/lmen,<11 5g/lwomen 8 7 9 8
TSF <5th P* 5 4 5 4
MAMC<5thP* 3 4 4 3
Body wt loss > 10% 8 6 10 10
*5th P= 5th percentile of the healthy standards for age and sex.'9
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PEN group, there were three treatment failures.
One of these patients improved when steroids
were administered. The remaining two patients
did not achieve remission after four weeks of
treatment. They also failed to respond to steroids
and were treated surgically. No preferential
disease location was noted in treatment failures.
Protein-energy nutritional status was main-
tained in both groups during the trial period.
Nutritional support induced a significant
increase in TSF, whereas normal hospital
diet plus steroids did not. Similar significant
increases in serum albumin concentration were
found in both groups (Table V).
Tolerance of the diet in the PEN group was
excellent. One patient complained of heartburn
and required the administration of H2 antagon-
ists to relieve it. It is remarkable that no patient
had diarrhoea attributable to diet intolerance,
and the number of bowel movements decreased
significantly in the PEN group (Table IV). Four
of the 17 (23-5%) patients in the steroid group
had complications attributable to the treatment
(two moon faces, one acne, and one hypo-
kalaemia), but no difference in treatment related
complication rate was found between groups
(p=021).
Fifteen patients relapsed during the follow up,
10 from the steroid group (66-6%) and five from
the PEN group (41 6%). No differences were
found in the cumulative relapse probability
during follow up (p=0.21) (figure). Follow up in
non-relapsing patients ranged from two to 41-7
months (median 9 1 months) in the PEN group,
and from 3-2 to 30-1 months (median 7-8
months) in the steroid group.
Discussion
To our knowledge, this is the first controlled trial
to compare a polymeric formula enteral diet v
steroids in the treatment of active Crohn's
disease. The results suggest that polymeric diets
are as safe and effective as steroids in inducing
short term remission. The mean difference of
reduction in the VHAI between treatments was
small. Also, there is only a probability of 0-025
that the true difference between treatment
groups in the population was greater than 16-8%
(upper limit of 95% CI). So it is unlikely that
clinically important differences have been over-
looked.
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TABLE IV Changes in clinical and biological indices during the trial
PEN (n= 15) Steroids (n= 17)
Initial Final p Value Initial Final p Value
No of bowel actions 2-6 (0 44) 1-8 (0 66) 0 04 2-8 (0 6) 1-2 (0-12) 0 01
Stool consistency* 2-5 (0-13) 1-5 (0-16) 0 0005 2-2 (0-16) 1-2 (0 09) 0 0001
Abdominalmass* 1-4(0-13) 1-2(0 11) NS 1-3(0 11) 1-2(0 09) NS
Temperature (C) 36-9 (0-1) 36-4 (0 1) 0-02 36-9 (0-1) 36-3 (0 06) 0-003
Pulse rate (beats/min) 85-1(2-5) 81-7 (2 05) NS 83-8 (2-4) 80-4 (2 7) NS
ESR (mm/h) 38-3 (5 8) 25-1(5 2) 0 001 47-7 (5 4) 22-7 (3 7) 0 0001
CRP (mg/l) 37-1 (6-1) 12-6 (4-1) 0-03 44-1(7 8) 8-6 (3 5) 0 01
Haemoglobin (g/dl) 11-6 (0-35) 12-05 (0 3) NS 11-8 (0-5) 12-15 (0 4) NS
Platelet count (x 109/1) 379 4 (29 4) 361 (22 2) NS 388 (23 2) 374 (25 6) NS
Leucocytecount(x103/l) 8-6(0 9) 8 5(0-7) NS 10-1(0-1) 11-6(1-0) NS
Lymphocyte count
(x 103/1) 2-1 (0 2) 2-2 (0 8) NS 1-7 (01) 3 0 (0 4) 0 001
Extraintestinal
complications 3/15 1/15 NS 5/17 1/17 NS
*Scores as expressed in the Van Hees activity index.
Values followed by parentheses are means (SEM).
Changes in the VHAI were used as an end
point in this study. This index, as it largely
depends on laboratory measurements, is more
objective than other indices including overall
clinical assessment, such as the Crohn's disease
activity index (CDAI).22-24 Also, the increase in
the number of liquid or soft stools, an important
item of CDAI, may be caused either because of
worsening of the intestinal disease or as a side
effect of enteral nutrition. This may induce
misjudgment. Moreover, the use of the reduc-
tion of the VHAI instead of CDAI as the end
point to calculate the sample size allowed us to
study a smaller sample of patients than in
previous work,10 for the same a and errors.
This is due to the smaller variability of VHAI
compared with CDAI.22-24
In a unique trial comparing a non-elemental
tube fed diet with steroids, Lochs et al suggested
that a peptide based diet was less effective than a
combination of methylprednisolone and sulfa-
salazine in treating active Crohn's disease.'0 The
different results obtained with the polymeric diet
used in our study are unlikely to be a conse-
quence of the different protein composition.
Peptides, less antigenic substrates than whole
protein, are effective in inducing remission in
Crohn's disease." Thus differences should be
attributed to other factors. As previously men-
tioned , the use of CDAI as the criteria to assess
clinical efficacy in the study ofLochs et almay be
controversial due to the importance of the
number ofbowel movements on the CDAI score.
The osmolality of the diet used was high (400
mOsm/kg) because, as well as peptides, it con-
tained medium chain triglycerides (60% of the
fat content). Thus this formula diet might
increase stool frequency and cause misleading
changes in the CDAI.
Our present study supports the view that
whole protein based diets are clinically effective,
as suggested in three previous trials that
compared this type of diet with elemental
formulas,'2`14 although in one of them'3 the
sample is small and the conclusions are only
indicative. Only in one study, by Giaffer et al,
was a poorer response found with a polymeric
diet compared with an elemental diet.'5 In this
trial the polymeric diet was discontinued for
ethical reasons when no improvement was found
by the 10th day of treatment. The results of this
trial can be questioned for several reasons.
Firstly, the groups studied were not homo-
geneous for the location of the disease. This
could have been avoided by stratified randomisa-
tion of the patients. Secondly, if the objective of
the study ofGiaffer et al was to ascertain whether
a particular form of nitrogen source (amino acid
v whole protein) had a primary beneficial effect,
both formula diets should have been equivalent
in carbohydrate and fat composition, and in fact
the amount of fat administered was 15 times
higher in the polymeric than in the elemental
diet.
Nutritional improvement itself does not seem
to have had a role in the effect of PEN in our
study. Although mean TSF increased signifi-
cantly in the PEN group, this improvement is
likely to be clinically irrelevant as no differences
were found in the number of patients with
abnormal TSF values before and after the trial.
The increase in serum albumin was similar in
both groups. Therefore, the effect ofPEN seems
to be mediated by changes in the inflammatory
activity. In fact, biological indices of inflamma-
tion (CRP, ESR) improved similarly in both
groups.
One fact seldom taken into account when
comparing diets in the treatment of Crohn's
disease is the possible differences in their fat
TABLE V Changes in nutritional indices during the trial
PEN (n= 15) Steroids (n= 17)
Initial Final p Value Initial Final p Value
Body weight (kg) 57-1(3 4) 58-3 (3-2) NS 57-8 (3 3) 58-2 (3 5) NS
IBW(%) 89-1(3-6) 91-1(3-3) NS 86-9(3 9) 87-4(4-1) NS
TSF (%) 675 (7-9) 73-4(6 8) 0 03 72-9(7 9) 745 (7 7) NS
MAMC(%) 108-1(2-9) 102-2(6 9) NS 96%5(5 2) 101-8(3 0) NS
Serumalbunmin(g/1) 34-2(1-2) 39-2(1-1) 0-006 33-6(1-4) 37-8(1-4) 0 01
Values are means (SEM). For abbreviations see table II.
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composition. Experimental work has been
reported in which the administration of low fat
diets25 or diets with low essential fatty acid
content26 have an immunomodulatory effect in
animal models. Also, essential fatty acid defici-
ency diminishes acute inflammation27 and
improves experimental colitis in rats.28 Recent
studies in vitro and in humans emphasise the
possible role offatty acids and their derivatives in
mediating inflammation.2"3" In this context, an
altered plasma pattern of polyunsaturated fatty
acids has been described in inflammatory bowel
disease.32
A careful examination of the reports of
elemental diets having a favourable effect on
Crohn's disease,"5 indicates that all of them had
very low fat content (0-6 to 1-3% of total
calories). When intermediate or high fat diets are
used,'2-'5 the favourable or unfavourable clinical
outcome might depend on the type of pre-
dominant fatty acids. In the present study, the
polymeric diet used had both high fat (33% ofthe
total calories) and high monounsaturated fatty
acid (oleic acid) content. By contrast, the poly-
meric diet used in the study of Giaffer et al was
high fat (36% of total calories) but also high in
linoleic acid. This fatty acid is the precursor of
arachidonic acid, which, in turn is the substrate
for eicosanoid (LTB4, TxA2, PGE2) synthesis.
Thus quantitative or qualitative differences in
the lipid composition of the administered fat,
saturated or monounsaturated v polyunsaturated
oils, may modify the synthesis of eicosanoids and
impair some immunomodulatory mechanisms
that may influence the outcome when treating
active Crohn's disease. Studies taking into
account the lipid composition of the diets may
help to further define the mechanism for the
primary effect of enteral diets in active Crohn's
disease.
In our present study, differences in relapse
during follow up between both groups were not
found, but relapse rate tended to be lower in the
PEN group. This suggests that the remissions
achieved with PEN were real, whatever the
mechanism. This trend has to be confirmed with
more patients and a longer follow up.
In conclusion, the results of our present study
suggest that polymeric diets are a safe and
effective treatment for active Crohn's disease.
They are a well tolerated and a cheaper alterna-
tive to elemental diets, which merit serious
consideration as treatment of active Crohn's
disease, specially in malnourished patients or
when steroid treatment is contraindicated.
Further studies in a larger series are needed to
ascertain which subgroups of patients with
Crohn's disease are more prone to respond to diet
treatment and to maintain longterm remission.
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